Brainstorm cell therapeutics inc. (BCLI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Operating expenses:
Research and development, net

5,948

6,186

4,008

3,554

3,456

3,860

1,975

1,481

977

-1,567

1,168

435

941

323

790

151

986

826

1,503

1,375

1,245

1,643

1,572

877

680

849

804

742

522

284

732

385

369

657

176

586

270

371

-348

General and administrative

2,360

1,479

1,543

1,303

1,472

1,577

1,257

1,606

1,330

1,329

1,224

640

829

327

848

832

826

571

1,068

988

960

1,023

858

417

351

552

272

743

559

350

440

448

510

554

564

829

258

264

-268

Financial expenses (income), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11

183

-46

191

-177

45

-2

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

264

0

-132

0

0

0

Operating loss

-8,308

-7,665

-5,551

-4,857

-4,928

-5,437

-3,232

-3,087

-2,307

238

-2,392

-1,075

-1,770

-650

-1,638

-983

-1,812

-1,397

-2,571

-2,363

-2,205

-1,586

-2,430

-1,294

-2,111

-1,236

-1,081

-1,500

-1,082

-578

-1,150

-829

-868

-5,016

-694

1,092

705

680

-

Total operating costs and expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,031

1,401

1,076

1,485

1,081

634

1,172

833

879

1,211

740

1,415

528

635

-616

Financial expenses (income), net

-194

27

83

43

99

-54

-56

4

-9

-38

11

-35

15

-26

-32

-21

-22

-13

32

-98

31

64

-9

690

1,080

-165

5

15

1

-

-22

-4

-

-

-

-

-

-

-

Total loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

614

Taxes on income (Note 12)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-19

1

18

0

0

0

1

4

10

0

-5

0

-24

0

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,082

-578

-1,150

-830

-872

-5,026

-694

1,097

705

704

614

Net loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Net loss

-8,114

-7,692

-5,634

-4,900

-5,027

-5,383

-3,176

-3,091

-2,298

276

-2,403

-1,040

-1,785

-624

-1,606

-962

-1,790

-1,384

-2,603

-2,265

-2,236

-2,730

-2,421

-1,984

-2,111

-1,217

-1,082

-1,518

-1,082

-578

-1,150

-830

-872

-3,616

-694

1,097

-705

704

614

Basic and diluted net loss per share from continuing operations

-0.32

-

-0.25

-0.23

-0.24

-

-0.15

-0.16

-0.12

0.03

-0.13

-0.06

-0.10

-0.03

-0.09

-0.05

-0.10

-0.08

-0.14

-0.12

-0.12

-0.54

-0.16

-0.16

0.18

0.34

0.10

0.01

0.01

0.05

-0.01

-0.01

-0.01

-0.04

-0.01

0.01

0.01

0.01

0.01

Weighted average number of shares outstanding used in computing basic and diluted net loss per share

28,423

22,749

22,254

21,703

20,917

20,746

20,691

19,505

19,047

18,898

18,783

18,738

18,688

18,688

18,656

18,654

18,653

18,562

18,480

18,450

18,128

15,322

15,158

12,416

11,753

-271,495

10,948

152,546

150,953

150,308

145,407

128,078

126,591

125,724

124,596

121,253

108,895

91,606

88,609